We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
On Friday, pharmaceutical giant McKesson Corp (MCK - Free Report) experienced a 24% drop in their stock price, down to $124.57, as of 3:15pm central. This comes after the release of their 2nd quarter fiscal 2017 earnings.
MCK reported revenue of $49.96B and earnings of $2.94 per share. These figures are lower than expectations, which projected earnings of $3.04 per share and revenue of $51.2B. MCK CEO John Hammerger explained how the company needed to lower drug prices in order to reciprocate competition. This explains the sudden drop in stock price, as investors displayed uncertainty in MCK’s future earnings.
Hammerger displayed annoyance while discussing competition and the drop in prices, saying, "What we began to see more recently is competitive activity that is broader than our original expectations, more aggressive, and across several areas of our U.S. pharmaceutical business. When a competitor significantly undercuts our existing pricing, we are compelled to respond."
The hope for MCK is that investors will see value in their impressive track record. Historically, the company has been able to post notable growth on both revenue and EPS, and recently, McKesson separated its technology sector from its other businesses. According to Zacks' MCK analysis summary page, McKesson "has been actively pursuing deals and acquisitions to drive growth. The separation of its Technology business into a new healthcare information technology that will enable the company to concentrate on the primary pharmaceuticals distribution business."
This explains why Zacks Rank had Value, Growth and VGM all rated at 'A' as of October 27, 2016. The company is showing growth and focus on their most profitable sector. However, with its current standing, it's clear to why the stock was downgraded from a #3 (Hold) to a #4 (Sell) on the Zacks Rank.
Interested in the other top stories of the week? Listen to Zacks Friday Finish Line to catch up on the week's financial and investment news.
Stocks that Aren't in the News…Yet
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street. They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015, with a stellar average gain of +26% per year. See these high-potential stocks now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson Corp (MCK) Stock Down Over 24% Today
On Friday, pharmaceutical giant McKesson Corp (MCK - Free Report) experienced a 24% drop in their stock price, down to $124.57, as of 3:15pm central. This comes after the release of their 2nd quarter fiscal 2017 earnings.
MCK reported revenue of $49.96B and earnings of $2.94 per share. These figures are lower than expectations, which projected earnings of $3.04 per share and revenue of $51.2B. MCK CEO John Hammerger explained how the company needed to lower drug prices in order to reciprocate competition. This explains the sudden drop in stock price, as investors displayed uncertainty in MCK’s future earnings.
Hammerger displayed annoyance while discussing competition and the drop in prices, saying, "What we began to see more recently is competitive activity that is broader than our original expectations, more aggressive, and across several areas of our U.S. pharmaceutical business. When a competitor significantly undercuts our existing pricing, we are compelled to respond."
The hope for MCK is that investors will see value in their impressive track record. Historically, the company has been able to post notable growth on both revenue and EPS, and recently, McKesson separated its technology sector from its other businesses. According to Zacks' MCK analysis summary page, McKesson "has been actively pursuing deals and acquisitions to drive growth. The separation of its Technology business into a new healthcare information technology that will enable the company to concentrate on the primary pharmaceuticals distribution business."
This explains why Zacks Rank had Value, Growth and VGM all rated at 'A' as of October 27, 2016. The company is showing growth and focus on their most profitable sector. However, with its current standing, it's clear to why the stock was downgraded from a #3 (Hold) to a #4 (Sell) on the Zacks Rank.
Interested in the other top stories of the week? Listen to Zacks Friday Finish Line to catch up on the week's financial and investment news.
Stocks that Aren't in the News…Yet
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street. They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015, with a stellar average gain of +26% per year. See these high-potential stocks now >>